CN103547240B - For the autonomic balance of the mankind and the system and method maintaining health - Google Patents
For the autonomic balance of the mankind and the system and method maintaining health Download PDFInfo
- Publication number
- CN103547240B CN103547240B CN201180070951.0A CN201180070951A CN103547240B CN 103547240 B CN103547240 B CN 103547240B CN 201180070951 A CN201180070951 A CN 201180070951A CN 103547240 B CN103547240 B CN 103547240B
- Authority
- CN
- China
- Prior art keywords
- patient
- neurotransmitter
- supplement
- neural
- scheme
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 230000002567 autonomic effect Effects 0.000 title claims description 6
- 238000000034 method Methods 0.000 title abstract description 20
- 230000036541 health Effects 0.000 title description 12
- 238000011282 treatment Methods 0.000 claims abstract description 89
- 239000002858 neurotransmitter agent Substances 0.000 claims abstract description 50
- 230000001537 neural effect Effects 0.000 claims abstract description 31
- 239000013589 supplement Substances 0.000 claims abstract description 26
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 claims abstract description 18
- 230000005611 electricity Effects 0.000 claims abstract description 17
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- 229960003692 gamma aminobutyric acid Drugs 0.000 claims abstract description 12
- 238000011287 therapeutic dose Methods 0.000 claims abstract description 7
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000000638 stimulation Effects 0.000 claims description 36
- 238000012423 maintenance Methods 0.000 claims description 4
- 210000003205 muscle Anatomy 0.000 claims description 4
- YBRIOADNXHWOSW-UHFFFAOYSA-N PHENYL-gamma-Aminobutyric Acid Chemical compound NCCC(C(O)=O)C1=CC=CC=C1 YBRIOADNXHWOSW-UHFFFAOYSA-N 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims 8
- 230000001225 therapeutic effect Effects 0.000 abstract description 25
- 210000002820 sympathetic nervous system Anatomy 0.000 abstract description 19
- 239000002243 precursor Substances 0.000 abstract description 18
- 230000008569 process Effects 0.000 abstract description 7
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 abstract description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 abstract description 6
- 230000004936 stimulating effect Effects 0.000 abstract description 6
- FMGSKLZLMKYGDP-USOAJAOKSA-N dehydroepiandrosterone Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC=C21 FMGSKLZLMKYGDP-USOAJAOKSA-N 0.000 abstract description 5
- 238000001879 gelation Methods 0.000 abstract description 5
- 210000001595 mastoid Anatomy 0.000 abstract description 4
- FMGSKLZLMKYGDP-UHFFFAOYSA-N Dehydroepiandrosterone Natural products C1C(O)CCC2(C)C3CCC(C)(C(CC4)=O)C4C3CC=C21 FMGSKLZLMKYGDP-UHFFFAOYSA-N 0.000 abstract description 3
- 229960002847 prasterone Drugs 0.000 abstract description 3
- 230000004044 response Effects 0.000 description 51
- 210000004556 brain Anatomy 0.000 description 41
- 208000019901 Anxiety disease Diseases 0.000 description 34
- 230000036506 anxiety Effects 0.000 description 33
- 230000001734 parasympathetic effect Effects 0.000 description 33
- 230000002889 sympathetic effect Effects 0.000 description 29
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 20
- 230000000694 effects Effects 0.000 description 16
- 230000008859 change Effects 0.000 description 15
- 210000002569 neuron Anatomy 0.000 description 14
- 238000010586 diagram Methods 0.000 description 13
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 12
- 230000010247 heart contraction Effects 0.000 description 10
- 210000005036 nerve Anatomy 0.000 description 10
- 210000005069 ears Anatomy 0.000 description 9
- 239000003550 marker Substances 0.000 description 9
- 230000033764 rhythmic process Effects 0.000 description 9
- 230000007958 sleep Effects 0.000 description 9
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 8
- 239000008280 blood Substances 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 8
- 230000000147 hypnotic effect Effects 0.000 description 8
- 230000035479 physiological effects, processes and functions Effects 0.000 description 8
- 230000009467 reduction Effects 0.000 description 8
- 230000008451 emotion Effects 0.000 description 7
- 238000002372 labelling Methods 0.000 description 7
- 210000003169 central nervous system Anatomy 0.000 description 6
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 230000006698 induction Effects 0.000 description 6
- 230000002045 lasting effect Effects 0.000 description 6
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 5
- LDCYZAJDBXYCGN-VIFPVBQESA-N 5-hydroxy-L-tryptophan Chemical compound C1=C(O)C=C2C(C[C@H](N)C(O)=O)=CNC2=C1 LDCYZAJDBXYCGN-VIFPVBQESA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 230000000747 cardiac effect Effects 0.000 description 5
- 230000001054 cortical effect Effects 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229960002748 norepinephrine Drugs 0.000 description 5
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 5
- 230000008447 perception Effects 0.000 description 5
- 230000035882 stress Effects 0.000 description 5
- 210000001103 thalamus Anatomy 0.000 description 5
- 239000003470 adrenal cortex hormone Substances 0.000 description 4
- 210000001320 hippocampus Anatomy 0.000 description 4
- 210000003016 hypothalamus Anatomy 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000003340 mental effect Effects 0.000 description 4
- 229960002888 oxitriptan Drugs 0.000 description 4
- 230000003518 presynaptic effect Effects 0.000 description 4
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 4
- 230000035807 sensation Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 229930003268 Vitamin C Natural products 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 230000005540 biological transmission Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 230000019771 cognition Effects 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 229960000890 hydrocortisone Drugs 0.000 description 3
- 239000011777 magnesium Substances 0.000 description 3
- 229910052749 magnesium Inorganic materials 0.000 description 3
- 230000015654 memory Effects 0.000 description 3
- 238000011084 recovery Methods 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 230000011664 signaling Effects 0.000 description 3
- 239000002438 stress hormone Substances 0.000 description 3
- 210000000225 synapse Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000019158 vitamin B6 Nutrition 0.000 description 3
- 239000011726 vitamin B6 Substances 0.000 description 3
- 235000019154 vitamin C Nutrition 0.000 description 3
- 239000011718 vitamin C Substances 0.000 description 3
- 229940011671 vitamin b6 Drugs 0.000 description 3
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 2
- 229930182837 (R)-adrenaline Natural products 0.000 description 2
- 102000012289 Corticotropin-Releasing Hormone Human genes 0.000 description 2
- 108010022152 Corticotropin-Releasing Hormone Proteins 0.000 description 2
- 239000000055 Corticotropin-Releasing Hormone Substances 0.000 description 2
- 102000009025 Endorphins Human genes 0.000 description 2
- 108010049140 Endorphins Proteins 0.000 description 2
- 102000005915 GABA Receptors Human genes 0.000 description 2
- 108010005551 GABA Receptors Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- YJPIGAIKUZMOQA-UHFFFAOYSA-N Melatonin Natural products COC1=CC=C2N(C(C)=O)C=C(CCN)C2=C1 YJPIGAIKUZMOQA-UHFFFAOYSA-N 0.000 description 2
- DATAGRPVKZEWHA-YFKPBYRVSA-N N(5)-ethyl-L-glutamine Chemical compound CCNC(=O)CC[C@H]([NH3+])C([O-])=O DATAGRPVKZEWHA-YFKPBYRVSA-N 0.000 description 2
- 125000003047 N-acetyl group Chemical group 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 235000005550 amino acid supplement Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 210000003403 autonomic nervous system Anatomy 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 210000004958 brain cell Anatomy 0.000 description 2
- 210000000621 bronchi Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 230000002996 emotional effect Effects 0.000 description 2
- 239000002702 enteric coating Substances 0.000 description 2
- 238000009505 enteric coating Methods 0.000 description 2
- 229960005139 epinephrine Drugs 0.000 description 2
- 230000002964 excitative effect Effects 0.000 description 2
- 210000003499 exocrine gland Anatomy 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229960003987 melatonin Drugs 0.000 description 2
- DRLFMBDRBRZALE-UHFFFAOYSA-N melatonin Chemical compound COC1=CC=C2NC=C(CCNC(C)=O)C2=C1 DRLFMBDRBRZALE-UHFFFAOYSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- DAFOCGYVTAOKAJ-UHFFFAOYSA-N phenibut Chemical compound OC(=O)CC(CN)C1=CC=CC=C1 DAFOCGYVTAOKAJ-UHFFFAOYSA-N 0.000 description 2
- 210000001013 sinoatrial node Anatomy 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- 230000001515 vagal effect Effects 0.000 description 2
- 210000001186 vagus nerve Anatomy 0.000 description 2
- 230000000007 visual effect Effects 0.000 description 2
- 206010001488 Aggression Diseases 0.000 description 1
- 206010002869 Anxiety symptoms Diseases 0.000 description 1
- 108010062745 Chloride Channels Proteins 0.000 description 1
- 102000011045 Chloride Channels Human genes 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 206010012373 Depressed level of consciousness Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010020852 Hypertonia Diseases 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010021567 Impulsive behaviour Diseases 0.000 description 1
- 206010022998 Irritability Diseases 0.000 description 1
- CAHKINHBCWCHCF-JTQLQIEISA-N N-acetyl-L-tyrosine Chemical compound CC(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 CAHKINHBCWCHCF-JTQLQIEISA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010033664 Panic attack Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 206010039897 Sedation Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000001353 anxiety effect Effects 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000035559 beat frequency Effects 0.000 description 1
- 229940093797 bioflavonoids Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 210000001715 carotid artery Anatomy 0.000 description 1
- 210000003710 cerebral cortex Anatomy 0.000 description 1
- 210000004720 cerebrum Anatomy 0.000 description 1
- 108091008690 chemoreceptors Proteins 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 230000037326 chronic stress Effects 0.000 description 1
- 230000001427 coherent effect Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 238000007599 discharging Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 210000001652 frontal lobe Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 239000000413 hydrolysate Substances 0.000 description 1
- 230000000640 hydroxylating effect Effects 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003212 lipotrophic effect Effects 0.000 description 1
- 230000007787 long-term memory Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 230000028161 membrane depolarization Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 229960001682 n-acetyltyrosine Drugs 0.000 description 1
- 230000007383 nerve stimulation Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001053 orthosympathetic effect Effects 0.000 description 1
- 230000010355 oscillation Effects 0.000 description 1
- 208000019906 panic disease Diseases 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 230000008560 physiological behavior Effects 0.000 description 1
- 230000007180 physiological regulation Effects 0.000 description 1
- 230000001242 postsynaptic effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 210000001747 pupil Anatomy 0.000 description 1
- 150000003248 quinolines Chemical group 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000002787 reinforcement Effects 0.000 description 1
- 230000002040 relaxant effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 210000005245 right atrium Anatomy 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036280 sedation Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 230000002557 soporific effect Effects 0.000 description 1
- GOLXNESZZPUPJE-UHFFFAOYSA-N spiromesifen Chemical compound CC1=CC(C)=CC(C)=C1C(C(O1)=O)=C(OC(=O)CC(C)(C)C)C11CCCC1 GOLXNESZZPUPJE-UHFFFAOYSA-N 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006190 sub-lingual tablet Substances 0.000 description 1
- 229940098466 sublingual tablet Drugs 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000000106 sweat gland Anatomy 0.000 description 1
- 230000035900 sweating Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000026676 system process Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940026510 theanine Drugs 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- 239000011721 thiamine Substances 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002936 tranquilizing effect Effects 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- 230000003639 vasoconstrictive effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/36—Applying electric currents by contact electrodes alternating or intermittent currents for stimulation
- A61N1/36014—External stimulators, e.g. with patch electrodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
- A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0472—Structure-related aspects
- A61N1/0492—Patch electrodes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Radiology & Medical Imaging (AREA)
- Organic Chemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Biophysics (AREA)
- Ophthalmology & Optometry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Provide be reduced in sympathetic nervous system in human body awakening to prepare therapeutic scheme or the process of medical treatment or dental operation for that people.First, dose a patient with one or more neurotransmitter supplement of the such as gamma-aminobutyric acid preparation of therapeutic dose, precursors of neurotransmitters that tryptophan derives and dehydroepiandrosterone.Thereupon, gelation electrode be placed on mastoid process contiguous or under.Gelatinous Electrode connection is to cranium electricity treatment stimulating apparatus, and cranium electricity treatment stimulating apparatus applies to feel lower horizontal electric current to patient.In addition, noise suppressed headband receiver is placed on patient to go up and neural acoustics recording or the program of playing traction.Next, sunglasses are used to shut out the light.Then, medical treatment or dental operation is performed.
Description
Technical field
The present invention relates to medical treatment and dental care, more particularly, relate to the anxiety being designed to the sympathetic nervous system awakening reduced in human body and reduce therapeutic scheme.
Background technology
Have and unnecessary and inappropriately often refuse required medical treatment and dental care about medical treatment and the fear of dental treatment and the individual of anxiety.Even if when this individual consent be medically treated or dental operation time, their fear and anxiety can make to experience unnecessarily unhappy, cause the medical outcome of suboptimum.Therefore, need a kind of for providing from anxiety and the frightened method alleviated and correct to individual in the preparation for medical treatment or dental operation.
Summary of the invention
Provide the awakening that is reduced in sympathetic nervous system in human body fast to make this human body be ready to be medically treated or the therapeutic scheme of dental operation or process, and this therapeutic scheme or process allow to return to rapidly pre induction (preinduction) state.First, one or more precursors of neurotransmitters of oral to patient or sublingual administration therapeutic dose, precursors of neurotransmitters, the tryptic hydrolysate precursors of neurotransmitters of casein and dehydroepiandrosterone (DHEA) that such as gamma-aminobutyric acid analog, 4-Amino-3-phenylbutyric acid (Phenibut) analog, tryptophan are derivative and analog supplement.Thereupon, gelation electrode is placed on mastoid process contiguous or under.Gelation Electrode connection is to cranium electricity treatment stimulating apparatus, and this cranium electricity treatment stimulating apparatus applies the electric current feeling lower level (sub-sensationlevel) to patient.In addition, noise suppressed headband receiver is placed on patient go up and play the recording of neural acoustics traction software or program.Next, sunglasses are used to shut out the light.Then, medical treatment or dental operation is performed.
Accompanying drawing explanation
Fig. 1 is the schematic block diagram that basic building block in the system for realizing therapeutic scheme of the present invention is shown.
Fig. 2 is a flow chart, for the method step that the process illustrated with perform therapeutic scheme of the present invention is associated.
Fig. 3 is a chart, for illustrating the physiological marker of the curative effect confirming therapeutic scheme of the present invention and the marker characteristic under sympathetic nerve and parasympathetic stimulation.
Fig. 4 is bar diagram, for illustrating the statistical remarkable trend of the physiological marker when applying therapeutic scheme of the present invention.
Fig. 5 is bar diagram, for illustrating the GSR response of complete treatment scheme and part treat scheme.
Fig. 6 is bar diagram, for illustrating the BVP amplitude response of complete treatment scheme and part treat scheme.
Fig. 7 A and 7B illustrates the figure of complete treatment scheme to the variations in temperature of baseline.
Fig. 8 is bar diagram, for illustrating the HRV amplitude response of complete treatment scheme and part treat scheme.
Fig. 9 is bar diagram, for illustrating the %HF response of complete treatment scheme and part treat scheme.
Figure 10 is bar diagram, for illustrating the %LF response of complete treatment scheme and part treat scheme.
Figure 11 is bar diagram, for illustrating the SDNN response of complete treatment scheme and part treat scheme.
Figure 12 is bar diagram, for illustrating the RMSSD response of complete treatment scheme and part treat scheme.
Figure 13 is bar diagram, for illustrating the SCP response of complete treatment scheme and part treat scheme.
Figure 14 is bar diagram, for illustrating the β amplitude response of complete treatment scheme and part treat scheme.
Figure 15 is bar diagram, for illustrating the δ amplitude response of complete treatment scheme and part treat scheme.
Figure 16 is bar diagram, for illustrating that the α of complete treatment scheme and part treat scheme exceeds the % response of θ.
Detailed description of the invention
Although following detail describes the various aspects in various embodiment of the present invention, but the rational technique personnel of this area will recognize, various change can be made in details of the present invention when not departing from the spirit and scope of the present invention defined in the appended claims.Therefore, should be appreciated that, unless otherwise prescribed, the present invention is not limited to the detail illustrating and describe here.
Fig. 1 is the figure of the component that therapeutic scheme 10 of the present invention is shown.In FIG, patient 12 receives noise suppressed stereophone 16, the dimmed eyeshield 18 of vision, cranium electrostimulator electrode 22 and neurotransmitter supplement 24.Neural acoustics traction signal generator 14 is connected to patient 12 by earphone 16.Cranium electricity treatment stimulating instrument 20 is connected to patient 12 by CES electrode 22.
Fig. 2 is for allowing patient be ready to be medically treated or the flow chart of an embodiment of step of therapeutic scheme of the present invention of dental operation.This method is reduced in rapidly sympathetic nervous system awakening in human body, to allow that people be ready to be medically treated or dental operation.Patient planned operation should be advanced to many 40 minutes arrival clinics.When being ready to start therapeutic scheme 30, patient is sitting in comfortable chaise longue 32.One or more neurotransmitteies similar thing/precursor supplement of therapeutic dose are taken to patient 34.Such as, to the derivative neurotransmitter 38 of patient's sublingual administration gamma-aminobutyric acid analog preparation (GABAa and GABAb agonist) 36, tryptophan and dehydroepiandrosterone 40.In an alternative embodiment, neurotransmitter similar thing/precursor supplement can be taken with the form of frost, this frost is applied by transdermal, is preferably applied to the neck area on carotid artery, and is applied to the region in each ear in vagal Arnold branch (ear branch).Thereupon, in step 42, gelation electrode 22 is placed contiguous or lower than mastoid process.Gelation electrode 22 is connected to and applies to feel that the cranium electricity treatment of lower horizontal electric current stimulates (CES) device 20 to patient, and optional intervalometer makes CES device 20 apply electric current to patient on continuous or intermittent basis.Patient places noise suppressed earphone 16, and plays neural acoustics traction recording or program 44.In step 46, medical treatment or dental operation is performed.
In one embodiment, only before dentistry or medical operating period implement that the treatment of cranium electricity stimulates, neural acoustics traction program and neurotransmitter similar thing/precursor additional project.In another embodiment, during dentistry or medical operating, if it is tediously long particularly to perform the operation, continue to apply that the treatment of cranium electricity stimulates, one or more in neural acoustics traction software program and neurotransmitter similar thing/precursor additional project.As shown in Figure 2, if necessary, the extra neurotransmitter of 52 patients similar thing/precursor supplement can be given.When this operation stops 54, stopping 56 cranium electricity treatments stimulates and neural acoustics traction program, and terminates 58 therapeutic schemes.
The invention discloses neurotransmitter similar thing/precursor supplement, the treatment of cranium electricity stimulate and neural acoustics traction software with bestow for to loosen and peacefulness feels that the stimulation of the neurotransmitter (that is, across the chemical substance that synapse transmission is got excited) be associated has cooperative compensating effect.Paragraph below describes for being about to be medically treated or the patient of dental operation implements the importance of these complementary schemes, object and benefit.
The neurobiology of pressure and awakening
The several system of human body participates in the reaction to pressure, comprises sensation thalamus, sensory cortex, hippocampus, corpus amygdaloideum, hypothalmus-pituitary-adrenal axis (hpa axis) and autonomic nervous system (ANS is made up of sympathetic nervous system (SNS) and parasympathetic nervous system (PNS)).In response to showing dangerous sensory stimuli, sensation thalamus is exchanged with corpus amygdaloideum by two approach.Thalamus is directly also exchanged to corpus amygdaloideum immediately by cortex underpass, and without any the cognition intervened.Thalamus is also exchanged with corpus amygdaloideum with hippocampus indirectly with more slowly by cortex.Store conscious memory and provide the hippocampus of environmental information and the cortex relevant to cognition to tell whether the threat of corpus amygdaloideum perception is real.
Corpus amygdaloideum stores implicit memory, such as the response with good conditionsi of the memory of aversive stimulus and the emotion relevant with fear.It comprises several core close but functionally different physically.The Basolateral complex process of corpus amygdaloideum is from the input of sensory system, and the significance of threat that perception and assessment are applied by the input of this sensory system.Its main output is the central nucleus of the corpus amygdaloideum participating in emotion awakening.This central nucleus sends the burst of frightened signaling to hypothalamus then.
Happen suddenly in response to frightened signaling, hypothalamus release is called as a kind of stress hormone of corticotropin-releasing factor (CRF), the adrenocortical hormone (ACTH) of its Stimulation of The Brain hypophysis release pressure hormone again then, it then again in stimulation of renal gland cortex to blood stream release corticosteroid hormone.The corticosteroid hormone of such as hydrocortisone for development health for danger fight or flight reaction be important.
Happen suddenly in response to frightened signaling, hypothalamus also activates sympathetic nervous system (SNS).Uncomfortable anxiety symptom is responsible in high SNS awakening.SNS by following manner by health prepare immediately with energetic defence behavior: tighten up muscle; Vasoconstrictive; Increase heart rate, metabolism and blood pressure and blood sugar level; The expansion pupil of eyes and the trachea and bronchus of pulmonary; Shunt blood is to skeletal muscle, liver, brain and the heart; Stimulate adrenal gland; And stimulate liver that glycogen is converted to glucose.Parasympathetic nervous system (PNS) on the contrary, heart beating of slowing down, shrink bronchus, and usually by physical recovery to normal condition.
SNS and PNS is acted on by the neurotransmitter of linking up along the nervous pathway of SNS and PNS.Each of SNS and PNS comprises (1) preganglionic neuron, and central nervous system (CNS) is connected to the neuroganglion of health by it; And (2) move towards the postganglionic neuron of effector organ from neuroganglion.
The neurotransmitter acetylcholine that Preganglionic sympathetic neuron release is excited, and Postganglionic sympathetic neuron release norepinephrine (being also referred to as norepinephrine).Because each neural SPN forms synapse with many postganglionic neurons usually, and because some neurons are directly to discharging norepinephrine and epinephrine (also referred to as epinephrine) in blood, so the activation of SNS affects several body function usually simultaneously.
As mentioned above, participating in pressure uses neurotransmitter to exchange with the nervous system of the physiological human body of anxiety.Two inhibitory neurotransmitters the most outstanding are γ-aminobutyric acid (GABA) and 5-hydroxy tryptamine.GABA is the main inhibitory neurotransmitter of central nervous system.GABA receptor finds on the 25-40% of brain synapse.When GABA is attached to GABA receptor, it opens chloride channel, and it allows electronegative chloride ion to enter the inside of neurocyte.This makes neuron polarize then, to forbid the presynaptic release of further neurotransmitter.By suppressing neural discharge, GABA suppresses the message that anxiety is relevant to arrive cortex.
When being subject to chronic stress or anxiety, brain exhausts the storage of its available GABA and other inhibitory neurotransmitters.This can finally cause full-blown anxiety or panic attack, with excessive sweating, tremble, muscular tone, weak, obnubilation, dyspnea, fear and other symptoms.
5-hydroxy tryptamine is a kind of neurotransmitter produced by the neuron of the nucleus ceruleus and rapheal nuclei that are arranged in brain.Nucleus ceruleus and rapheal nuclei domination thalamus, cerebral cortex and hippocampus.Low-level 5-hydroxy tryptamine is associated with depression, anxiety, insomnia, impulsive behavior, invasion and violent behavior.
Neurotransmitter supplements
In the use of the precursors of neurotransmitters supplement of the therapeutic dose of the preferred embodiments of the present invention, the angst resistance effect had brain by alleviation anxiety and the anxiety reducing patient.
In one embodiment, the amino acid preparation of the therapeutic dose that doses a patient with, it comprises: the magnesium (form with Magnesium taurinate .) of 1-6 milligram; The GABA of 50-200 milligram and phenyl-γ-aminobutyric acid; The glycine of 10 ~ 80 milligrams; The N-acetyl-L-tyrosine of 10 ~ 40 milligrams; And, 5-20 milligram taurine (also with the form of Magnesium taurinate .).Containing three main inhibitory neurotransmitter additional N-acetyl group TYRs in this preparation, N-acetyl group TYR is the precursor of another kind of neurotransmitter norepinephrine.The neuron of said preparation together for brain is inhibited, and because this reducing the awakening of sympathetic nervous system.Preferably to chew or the form of sublingual tablet or sublingual administration anti-fatty liver spray takes said preparation with one or more.By sublingual administration said preparation, said preparation is absorbed directly into blood by the blood vessel under tongue and in two cheeks, allows said preparation to be input to fast in system and to pass through blood brain barrier.
In a second embodiment, dose a patient with a kind of neurotransmitter supplementing preparation, and it contains the combination of following compositions: vitamin B6, vitamin C, bioflavonoids and tryptophan or L-5-hydroxytryptophan (L-5-HTP) and casein tryptic hydrolysates (CTH).The therapeutic dose of such combination contains the CTH of the L-thiamine of 25-400 milligram, the L-5-hydroxytryptophan of 10 ~ 150 milligrams, the 2-methyl-3-hydroxy-4-formyl-5-hydroxymethylpyridine .-5 '-phosphate ester (that is, vitamin B6) of 20-100 milligram and 100-800 milligram ascorbic acid (i.e. vitamin C) and 5-500 milligram.Patient may determine actual close rate for the response of self of therapeutic scheme.Amino acid preparation as above is such, and 5-hydroxy tryptamine promotes preparation and takes preferably by one or more tablet or lipotropic spray Sublingual.Or the form of the enteric coatings capsule Gong swallowing to anticipate takes it.Enteric coatings makes capsule walk around enzyme under one's belt, and this enzyme converts L-5-HTP to 5-hydroxy tryptamine too early before arrival central nervous system.
The precursors of neurotransmitters that tryptophan derives is as the precursor of the synthesis for 5-hydroxy tryptamine (that is, 5HTP or 5-HTP) and melatonin (melatonin).Vitamin B6 is the cofactor for 5HTP enzyme being converted to 5-hydroxy tryptamine, and Catalyzed by Vitamin C tryptophan is to the hydroxylating of 5-hydroxy tryptamine.
In the third embodiment, dose a patient with dehydroepiandrosterone (DHEA).Nature is a signal indicator by the hormone dehydroepiandrosterone of acth secretion, and it reduces the level of stress hormone hydrocortisone in vivo.This increase to preparation provides individual some whole bodies in Chronic Pressure and/or anxiety to discharge.
Preferred embodiment bestows the part or all of combination of above-mentioned supplement.
Neural acoustics traction
Be intended to arouse in conjunction with neural acoustics traction software in the preferred embodiments of the present invention and relax with generation, some frequency of brain wave dissociating relevant with the first stage of sleeping.
The electrochemical activity of brain produces measurable electromagnetic form.The electroencephalogram (EEG) of brain can quantize this activity in amplitude and frequency.Different brain wave frequencies is associated from different mental statuss by research.Frequency (that is, β E.E.G) place between 13 and 40 hertz, brains is active, vigilance also can be absorbed in details.β E.E.G state is associated with dialogue and emulative physical exertion.Between 8 and 13 hertz (that is, alpha state), brains more loosens and reacts fast.Alpha state and creativity, ponder and be associated with visual.The θ E.E.G state run in the scope of 4 to 8 hertz and daydream, powerful creativity, visual capacity, meditate and go out body experience and be associated.Brain cell resets their sodium and the ratio of potassium in θ state, and what sleep this contributes to being interpreted as the mental function of health is very important.The δ E.E.G state run in the scope of 0.5 to 4 hertz is associated with longterm memory with unconscious, very dark and without dream sleep.Some have the meditation of experience and discipline individual that their brains can both be trained to run in δ state conscious while very much.
The brain of a normal Healthy People cycles through each of these E.E.G states on whole daytime and evening.Further, because be not that all position of brain is active equally at any time, brain runs usually simultaneously in several E.E.G state.The state of mind of a people or level of consciousness are associated with prevailing E.E.G state usually.
Also believe, some brain wave frequencies promote production and the transmission of some neurotransmitter more than other brain wave frequencies.The generation of the brainwave patterns of 10Hz and the reinforcement of 5-hydroxy tryptamine and turnover are associated.For this reason, can believe, by by brain traction to a given frequency, the generation of some neurotransmitteies can be strengthened.
There are the various methods of traction E.E.G state, comprise discipline and sit in meditation, recite scripture and hypnosis.Most methods arouses brain for the response run a given E.E.G state by following manner: make brain stand repetitive stimulation, as the pulse of sound, volume modulation, monaural beat, ears beat or light pulse.10 hertz of stimulations to the constant repetition of brain applying can stimulate the E.E.G state of 10 hertz.This phenomenon is called as " frequency following response ".
In the preferred embodiment of the present invention, noise suppressed earphone is placed on the ear of patient, and is connected to neural acoustics traction recording (being numerical software file in a preferred embodiment).In one embodiment, recording preferably includes sound or music, and it is being designed to arouse higher levels of α or θ E.E.G and reduce β brain wave frequency place carry out volume modulation.
In another embodiment, recording is designed to make the one or more ears beat of brain perceive.When present the signal of two kinds of different frequencies respectively and one, each ear time, ears beat occurs.Each ear is hardwired to the hard Nux Canarii albi (the acoustic processing center of brain) in corresponding cerebral hemisphere.Brain is attempting to be in harmonious proportion its perception from the different noise that each ear is heard " ears beat ".If to an ear frequence of exposure 100Hz, and to another frequence of exposure 105 hertz, then brain is by the ears beat of perception 5Hz, and finally may by traction at this ears beat frequency place resonance.
In a preferred embodiment of the invention, neural acoustics traction software application introduces the recording of multiple ears frequency, and this recording preferably has the form of the ears frequency of harmonic wave layering and patterning.By this way, trigger the response of multiple frequency following in the brain simultaneously.In addition, preferably, the ears frequency of neural acoustics traction software is together with the sound making people relieved of instrumental music, rain or natural sound mixture.
The treatment of cranium electricity stimulates
In the preferred embodiments of the present invention, stimulate (CES) to be intended to stimulate the balance in the release and transmission of neural irritability and inhibition class neurotransmitter in conjunction with the treatment of cranium electricity.Be also referred to as micro-electric current electricity irritation or be apply low-level pulse-type current to head through the CES of cranium microelectric current.Preferably, via in mastoid process or under conducting resinl electrode to patient's delivered current.
Preferably provide electric current with the form of the Square wave pulses of sinusoidal, rectangle or amendment.Frequency is arranged on 0.1 and 1, between 000 hertz, is optionally superimposed upon on the carrier wave up to 150 kilo hertzs.Waveform is preferably two-phase and ambipolar, and has the dutycycle of 20% to 50%.Current intensity is set at the maintenance level (such as, between 0.01mA and 7mA, being more preferably about 0.1mA) below the threshold of feelings.CES device 240 should be able to adjust the voltage of the resistance for changing level, to provide the electric current of maintenance level.CES is preferably applied at least 30 minutes, and reaches 6 hours.Pattern of can adjusting frequency every now and then and levels of current are to prevent physiological regulation.
CES is considered to vagus nerve stimulation, and thus promotes PNS dominance.CES also by the hypothalamic areas of current focusing at brain, wherein, it affect the nerves mediator presynaptic release and the postsynaptic reception both.Electric current increases the cell leakage of brain cell by low-level electrophoresis, and this low-level electrophoresis improves the absorption of neurotransmitter.Electric current increase 5-hydroxy tryptamine in the brain and endorphin levels, and the level reducing stress hormone hydrocortisone in the brain.It also promotes alpha state.Believe that it accelerates their suppression and the manufacture of excitatory neurotransmitter and receive to run with identical speed by stimulating the neuron of brain, thus make them mutually suppress the further generation of the other side, neurotransmitter is returned to the homoiostasis before pressure.Such as, the CES applied to Anxiety Patients can slow down patient norepinephrine neuron and accelerate the neuron of endorphins of patient, make them reach homoiostasis.For this reason, CES is considered to have more theatrical effect for the Anxiety Patients losing balance than the patient loosened in vivo in balance.
Potentiation benefit
Collaborative neural acoustics traction software, precursors of neurotransmitters/analog supplement, electricity irritation and the shading eyeglasses of using has a lot of potentiation benefits.CES and neural acoustics traction promote all rapidly the homoiostasis between sympathetic nerve and parasympathetic nervous system, thus reduce sympathetic system awakening.The utilization of CES together with neural acoustics traction may obtain than being used alone neural acoustics traction the alpha state promoting more to loosen.The use of neurotransmitter supplement contributes to preventing presynaptic vesicle exhausted, and presynaptic vesicle exhaustion can not obtain enough precusor amino acids else and if then may occur together with CES.In addition, the release increasing inhibitory neurotransmitter is treated for all three kinds.The excitatory neuron event forming the basis of severe anxiety has been corrected in the homeostatic recovery of neuro chemistry.After stopped treatment scheme, there is one to the fast quick-recovery of original state, and have no side effect.
The blind research of list carrying out conformation is to collect data to support use studied therapeutic scheme to help experience that they carry out the Anxiety Patients of performing the operation, and this operation causes the serious anxiety of their needs calmness in the past.A small sample with the experimenter of the anxiety of bringing out is exposed in complete therapeutic scheme that the treatment of cranium electricity stimulates, neural acoustic software and the amino acid supplements taken, and this amino acid supplements taken is made up of GABA, 5HTP, the theanine with cofactor.In this research, experimenter accepts above-mentioned all parts at second day, and except replacing neural acoustic software by non-neural acoustic software (music of releiving), this is called as dummy treatment.
Research is divided into two stages.Stage I comprises the measurement of GSR.The data of collecting from experimenter in second stage are included in GSR reading and the electroencephalogram of " CZ " acquisition.Use ThoughtTechnologiesBioGraphProComp: version 2 .0 records all data.Passage α, θ, β and GSR is selected to for analyzing.Anxiety investigation is amended anxiety list of the check, givenly brings out rear anxiety, and is then daily treated afterwards again two treatments.
When data being compared, experimenter is exposed to complete treatment, and this complete treatment shows that produce than dummy treatment, the reduction of 30 on anxiety level and 4.47 microvolts on GSR record minimizing on average.Compare dummy treatment, from the eeg data display that neural acoustic software is treated, the mean reduction on β E.E.G power of-0.30, represents the reduction in vigilance and the increase on loosening.In addition, θ and α E.E.G is presented at the increase on power, and θ is+0.7 and α is+1.8.These represent that experimenter becomes more easily with quiet both increasing.This and dummy treatment are formed and contrast, and this dummy treatment is presented at the difference (less loosen) of the increase (more vigilance) on β, the reduction (more unquiet) of-0.05 microvolt on θ and 1.34 microvolts on α.When θ and α power increases.Experimenter becomes lighter, and therefore more may be not easy mad making an uproar during medical treatment or dental operation.
Together with E.E.G and GSR data, requisite is the viewing reduction of experimenter in the anxiety of perception, and this indicates by their anxiety mark and their reflection after studying every day.Experimenter is reflected, utilize two therapeutic schemes, they feel more to loosen, but have received that day of complete therapeutic scheme at them, their thought can let their thinking fly away, and they become receive false neural acoustic software than them that day easily and much tranquil.They report, they feel can to manage their pressure better than part treat after complete treatment and anxiety causes situation.Neural acoustic software, when using together with supplement with CES, is loosened than more promptly reduction anxiety and the increase when being used alone CES and supplement.
Human Physiology homoiostasis
Balance between autonomic sympathetic nerve and parasympathetic branches is most important for Human Physiology homoiostasis.Autonomic nervous system receives input from the part of central nervous system, central nervous system's process and the stimulation integrated from health and external environment condition.The action of parasympathetic nervous system may be summarized to be has a rest and recovers.Vagus nerve comprises about 75% in all parasympathetic fibers.Prevailing sympathetic nervous system response is the driver of many negative physiological and mental status.The consequence of these metabolism has good grounds in the prior art.Calm functional level requires that health is being in the leading state of parasympathetic nervous.
Physiological marker
Can obtain many physiological marker, it provides data to analyze clinical system of the present invention effect in the response reducing sympathetic nervous system and anxiety.These labellings comprise: skin scale cancer, temperature, blood volume pulse, heart rate, heart rate variability (comprising HRV amplitude, SDNN, RMSSD, %LF, %HF and LF/HF) and E.E.G (comprise α, θ, β and δ amplitude, α θ intersects and slow cortical potential).As shown in Figure 3, each in these physiological marker demonstrates specifically response under sympathetic nerve and parasympathetic stimulation (increase or reduce).
Skin scale cancer (GSR) is the method for the conductivity of the skin that a kind of measurement changes along with its level of wetness.This is significant, because sympathetic nervous system controls exocrine gland, so skin conductivity is used as the instruction of psychology or physiology awakening.Relation is there is between sympathetic activity and the awakening of such as frightened and angry emotion.GSR is extremely sensitive for the emotion in some.Mankind's exocrine gland is from the sympathetic choline function fiber accepts main signal controlled by neurotransmitter acetylcholine.In measurement GSR, very slight electric current is through skin, and the change of the salt measured in sudoriferous duct and water.Subject is more waken up emotion, then sweat gland activity is higher, and the conductivity of skin is larger.GSR along with sympathetic stimulation occur increase, and along with parasympathetic stimulation reduce.
Skin temperature is another the measuring of sympathetic nerve awakening.Skin temperature reduces along with sympathetic stimulation, and increases along with parasympathetic stimulation.
Blood volume pulse (BVP) utilizes photoelectric plethysmograph to measure, and photoelectric plethysmograph is a kind of sensor of Noninvasive, for measuring the relative changes of the blood volume in the finger or temple of experimenter.Infrared light supply is through tissue or from Tissue reflectance, this is detected by phototransistor, and is quantized with arbitrary unit.When blood flow is larger, fewer light is absorbed, and the intensity arriving the light of sensor increases.The waveform obtained from such sensor represents the BVP of experimenter, and BVP is with the phase place change of each heart beating on blood flow volume.Heart rate is only the heart beating quantity of each interval.Heart rate increases along with sympathetic stimulation, and reduces along with parasympathetic stimulation.BVP increases along with sympathetic stimulation equally, and along with parasympathetic stimulation reduction.
Heart rate variability (HRV) is made up of the difference of the heart beating on the interval between successive heartbeat to heart beating.Usually, emotional stress can cause seeming irregular and unstable cardiac rhythm pattern.Heart rate variability (HRV) waveform appears as a series of uneven jagged peak under stress, that is, incoherent cardiac rhythm pattern.From physiological angle, this pattern represents the signal step different from each other produced by autonomic Liang Ge branch.This incoherent pattern of the physiological behavior relevant with intense strain is run with can making health inefficiency, consumed energy, and on health, produce extra wearing and tearing.If emotional stress is long-term or frequently, then this is especially true.During positive emotion, cardiac rhythm pattern becomes high-sequential, looks like the ripple of a level and smooth harmony.This is called as coherent cardiac rhythm mode.For relevant cardiac rhythm, the behavior synchronously in autonomic Liang Ge branch, and the system of health is run with the efficiency improved and harmony analysis matrix.
HRV data can identify that anxiety and pressure are on the impact of cardiovascular system.Interval between heart beating is the starting point that be can be observed parasympathetic nervous and orthosympathetic impact by it.HRV the measuring to the change of eartbeat interval that be heart beating.The HRV increased has been shown having positive clinical meaning, and the HRV reduced then is associated with negative clinical effectiveness and condition.Be input by the several differences to sinuatrial node the physiological phenomenon that causes in heart beating to the change in eartbeat interval, sinuatrial node is the pacemaker tissue of the generation burst being arranged in heart right atrium, and is therefore the generator of normal sinus rhythm.Main input is sympathetic nerve and parasympathetic nervous system.Two main fluctuations are hennig-Lommel signs, and low-frequency oscillation is associated with the Mayer wave (waveform on the arteriotony brought by pressure receptor and chemoreceptor reflex control system) of blood pressure.
Time domain approach and frequency domain method for measuring the most widely used method of heart rate variability.Time domain approach is based on the interval of the heart beating analyzed in every way to heart beating or NN.Comprise the standard deviation at SDNN(NN interval in these) and the square root of mean square deviation of RMSSD(N continuous N).These are the tolerance representing sympathetic nerve or parasympathetic impact.The mark of these increases of measuring represents larger parasympathetic impact.The specification of these tolerance is: RMSSD27.2+/-12.3 and SDNN136.5+/-33.4.
LF, normalized LF, HF, normalized HF and LF/HF ratio is comprised with the measurement of frequency domain method assessment.The sympathetic nerve of the rhythm and pace of moving things reflection mixing of the HRV in low frequency (LF) scope (between 0.04 to 0.15 hertz) and parasympathetic activity.It is movable that stress increases LF, and be usually considered to the labelling of sympathetic nerve modulation.High frequency (HF) scope (between 0.15 to 0.4Hz) comprises the rhythm and pace of moving things utilizing parasympathetic activity to regulate, and corresponds to by breathing the N-N change caused.Dark even breathing activity-stimulat parasympathetic nervous system, and increase the amplitude of HF.It is movable that stress reduces HF.Vagal activity is the significant contributor for high fdrequency component.
Use LF/HF ratio, high numeral means the leading position of sympathetic activity, and low numeral means the leading position of parasympathetic activity.Dark with even breathing after, increase the change being reflected in parasympathetic nervous and regulating.HRV reduces along with sympathetic stimulation, and increases along with parasympathetic stimulation.Consistent with this result, HRVLF% and LF/HF ratio increases along with sympathetic stimulation, and reduces along with parasympathetic stimulation.
Various E.E.G is associated to clear-headed and sleep state, the mental activity relevant with cognition, sensation and the activity of motion and such as emotion that is frightened and anxiety.β E.E.G is E.E.G the most rapidly, and reflects normal clear-headed consciousness.β amplitude increases along with sympathetic stimulation.There is a series of β ripple: low β, easily but vigilance (13-15 hertz); Medium β (about 15-19 hertz); And high β, anxiety brain (being associated with frightened and anxiety), shows the frequency of brain wave between 23-38 hertz.α wave table shows a comfortable state loosened, 8-13 hertz, and with loosen, meditate and to be leisurely and carefreely associated.θ ripple reflects the state loosened deeply, 4-8 hertz.δ ripple instruction sleep state, wherein, signal is very slowly mobile by neuron colony, 4 hertz.δ amplitude gradually reduces between sleep period.δ ripple is to the V ripple occurred between sleep period with cortical potential (the following describes) is relevant slowly.
The generation of α with θ pattern in the brain to loosen respond relevant.Loosen response and reduce HRV index, relaxed muscle, and increase the oxygen supply to brain.Fight or flight response is along with β brain wave frequency (short arc, altofrequency).Loosen response and reduce HRV index, relaxed muscle, and increase the oxygen stream to brain.Loosen response be very conducive to study and deal with problems, and along with α (higher amplitude, low-frequency E.E.G) and theta rhythm (larger amplitude, low-frequency E.E.G).Frequency of brain wave increases along with sympathetic stimulation, and reduces along with parasympathetic stimulation.
Before α to θ intersection just in time occurs in sleep, provide the experience of the hypnosis of the deep separation loosened.α to θ intersects at the loss recovering the heart of sleep and the sensation of when and where.This is called as healing district or psychological separation state.State of consciousness is similar to the state of meditation or hypnotic relaxation.The state that α to θ crossing condition is loosened at the α (8-12 hertz) just on the edge of sleeping and the degree of depth in θ (4-8 hertz) scope.This name derives from the behavior of E.E.G.α ripple is usually high in amplitude than θ, or more powerful.When α ripple amplitude decline and the amplitude of θ rises to the point that it intersects with α ripple, this means that it has become more powerful, by claimed α to θ intersect.α θ intersects along with sympathetic stimulation reduces, and along with parasympathetic stimulation increase.
Slow cortical potential (SCP) be continue from 300 milliseconds to several seconds, lower than the frequency range of 1-2Hz cortex dendron transmembrane potential on gradually change.Nagative potential displacement show mobile or higher can incentive, what positive SCP displacement represented the reduction of neuronic activity can incentive or suppression.The depolarization of the cortical cell collection that the slow cortical potential displacement reflection in electric negative direction is large, reduces their excited threshold value.SCP increases along with sympathetic stimulation, and reduces along with parasympathetic stimulation.
Can find out in figure 3, each of these biophysics labellings has contrary response for sympathetic with parasympathetic stimulation.Such as, skin scale cancer increases along with sympathetic stimulation, and reduces with parasympathetic stimulation.Equally, electroencephalogram β amplitude, heart rate variability metrics LF/HF and HRVLF% increase along with sympathetic stimulation, and reduce along with parasympathetic stimulation.Otherwise skin temperature and heart rate variability amplitude reduce along with sympathetic stimulation, and increase along with parasympathetic stimulation.
Carried out in the research of the impact assessing therapeutic scheme of the present invention, before being exposed to complete therapeutic scheme and part treat scheme, and afterwards, being collected the data set of each for these key organism physiological marker therebetween.Make comparisons with part treat scheme, the impact that the present invention combines various mode to produce the enlarging markedly (SCP reduces) statistically in parasympathetic tone (relaxing), hypnosis and sleep state and brain activate in the individuality using complete treatment Regimen Chemotherapy of the present invention.As shown in Figure 3, biological physiology data confirm, complete treatment scheme of the present invention produces the change consistent with the sedation hypnotic effect dominated with parasympathetic nervous on biological physiology labelling.On the contrary, those experimenters being exposed to part treat scheme do not show the significant change on physiological marker.That the enhancement effect of the novelty of complete treatment scheme of the present invention and it are proved by the minimizing of the awakening of sympathetic nervous system, in rapid minimizing anxiety effect that these results confirm.
In current research, the non-anxiety volunteer of 30 random different health status is tested: be first exposed to complete treatment scheme of the present invention by following manner, then part treat scheme (after at least 48 hours) is exposed to, to identify the potentiation benefit of therapeutic combination of the present invention.Under study for action, the experimenter of receiving portion therapeutic scheme takes precursors of neurotransmitters/analog supplement, and the cranium electricity treatment being received in 100Hz setting stimulates.Those experimenters accepting complete treatment scheme of the present invention accept precursors of neurotransmitters/analog supplement, are arranged on the electric neural acoustics traction software for the treatment of stimulation, sunglasses and having music of the cranium of 0.5 hertz.
Key organism physiological signal was collected before and after, during the exposure of those experimenters in two kinds of therapeutic schemes.Collect data from complete and part treat scheme, and data and each baseline that the residual action because of complete treatment scheme causes are made comparisons.For the residual action comparison base data from complete treatment Regimen Chemotherapy.Object to assess interior change from the process of complete treatment scheme and distinctive residual action.Used available statistical analysis software to carry out effort represents the reliability of the data of the parasympathetic tone increased with display.
As bright in institute's accompanying drawing digital watch, perform the data analysis for each physiological marker by following manner: during the application of complete and part treat scheme, levy the change of mark value from baseline by multiple time diffusion segment table.The analysis display of these Study and Comparisons between complete and part treat protocol collection is (nonrandom) trend relevant statistically in special time period and on the persistent period of test in both data.
The experimenter accepting complete treatment scheme of the present invention is in parasympathetic nervous and more accounts in leading state, and the change in biological physiology labelling as shown in FIG. 4 proves.Fig. 4 shows complete treatment scheme and have significant effect statistically for the labelling of instruction parasympathetic nervous response in which kind of degree.Fig. 5 shows the GSR response of complete treatment scheme 102 and part treat scheme 104.The GSR response of complete treatment scheme 102 presents downward trend, has rapid induction, lasting effect and recovers rapidly to normal.Fig. 6 shows the BVP amplitude response of complete treatment scheme 106 and part treat scheme 108.Complete treatment scheme 106 BVP amplitude-frequency response increase, there is rapid induction and lasting effect.Fig. 7 A and 7B shows the variations in temperature of baseline 146 pairs of complete treatment schemes 148.The skin temperature response of complete treatment scheme is risen sharply, and stablizes and maintains the temperature place of rising compared with datum temperature.
Fig. 8 shows the HRV amplitude response of complete treatment scheme 110 and part treat scheme 112.The HRV amplitude response of complete treatment scheme increases, and display has the accumulative effect of the remarkable improvement relative to the baseline being after exposure continued above 48 hours.Fig. 9 shows the %HF response of complete treatment scheme 118 and part treat scheme 120.The %HF response display of complete treatment scheme increases parasympathetic dominance along with turning back to normal.Figure 10 shows the %LF response of complete treatment scheme 122 and part treat scheme 124.The %LF response of complete treatment scheme shows rapid minimizing, lasting effect and recovers rapidly to normal.
Figure 11 shows the SDNN response of complete treatment scheme 130 and part treat scheme 132.Complete treatment scheme SDNN response show the gradually increase of HRV during therapeutic scheme, after exposure more than 48 hours after continue and increase.Some experimenters show in four week period increases 30-70%.Figure 12 shows the RMSSD response of complete treatment scheme 134 and part treat scheme 136.The RMSSD response of complete treatment scheme shows the gradually increase of HRV during therapeutic scheme, after exposure and increase lasting more than 48 hours.Some experimenters show in four week period increases 30-70%.The heart rate response of complete treatment scheme declines, and the LF/HF ratio of complete treatment scheme reduces.In general, the HRV under complete treatment scheme of the present invention analyzes the coherence showing the increase of cardiovascular status.
Figure 13 shows the SCP response of complete treatment scheme 138 and part treat scheme 140.The SCP response of complete treatment scheme shows rapid induction (the larger blood flow to cortex of frontal lobe), the effect continued and recovers rapidly to normal.Figure 14 shows the β amplitude response of complete treatment scheme 142 and part treat scheme 144.The quick minimizing of the β amplitude-frequency response display awakening of complete treatment scheme and the parasympathetic tone of increase, lasting effect and maintenance.Utilize complete treatment scheme of the present invention, the intermediate frequency of E.E.G is reduced to 11.5 hertz from 17.3Hz.
Utilize complete treatment scheme of the present invention, α θ crossing event increases to nine events from an event during section at one time.Result shows, makes comparisons with part treat scheme, and the treatment of complete treatment scheme has significant change statistically on biological physiology labelling, shows the movement to the more state of parasympathetic nervous (less awakening, hypnosis), has larger α E.E.G dominance.The tranquilizing soporific traction of this separation keeps in the application process of complete treatment scheme of the present invention, and is confirmed in the biological physiology data of collected all categories.Figure 15 shows the δ amplitude response of complete treatment scheme 126 and part treat scheme 128.The δ amplitude response of complete treatment scheme shows quick hypnosis induction, the effect continued and recovers rapidly normal.The α that Figure 16 shows complete treatment scheme 114 and part treat scheme 116 responds more than the % of θ.The α of complete treatment scheme demonstrates quick hypnosis induction more than the % response of θ, has lasting effect and quickly recover to normal condition.
Conclusion
From being appreciated that therapeutic modality of the present invention has treatment use for the individuality had dentistry and other medical operating are reacted with severe anxiety above.Other benefits of the present invention and application will be apparent for those skilled in the art.
Term " precursors of neurotransmitters/analog supplement " used in the appended claims not only refers to natural neurotransmitter supplement, also refers to that health is used for synthesizing neurotransmitter, forbidding the re uptake of neurotransmitter or have the chemical supplement of the effect being similar to natural neurotransmitter.
Although aforesaid detail describes various embodiment of the present invention, but this area rational technique personnel will recognize, when not departing from the spirit and scope of the present invention limited in the appended claims, various change can be made to the details of equipment of the present invention.Therefore, it should be understood that unless otherwise prescribed, the present invention is not limited to the detail illustrating and describe here.
Claims (6)
1. a therapy system, for promoting autonomic balance and healthy maintenance fast, described therapy system is used for use collaborative with patient, and described therapy system comprises:
(a) neurotransmitter supplement of therapeutic dose for dosing a patient with, wherein said neurotransmitter supplement are selected from γ-aminobutyric acid, phenyl-gamma-aminobutyric acid preparation and its combination;
B () is for reducing or eliminating the dimmed eyeshield of vision of the intensity of the surround lighting be incident on the eyes of patient;
C () is in the permission support of patient and swing back at least in part in the position of mobile loosening all muscles, the support platform of supporting patient;
D () is connected to the cranium electricity treatment stimulation apparatus of patient; And
E () is connected to the neural acoustics traction system of patient, described neural acoustics traction system comprises neural acoustics traction signal generator and earphone, and described neural acoustics traction system is that each ear of patient generates respectively and the signal tone of side by side present two different frequencies.
2. therapy system according to claim 1, wherein, described neurotransmitter supplement are γ-aminobutyric acid (GABA).
3. therapy system according to claim 1, wherein, described neurotransmitter supplement comprise phenyl-γ-aminobutyric acid.
4. therapy system according to claim 1, wherein, described neurotransmitter supplement have and are suitable for oral form.
5. therapy system according to claim 1, wherein, described neurotransmitter supplement have the form being suitable for sublingual administration administration.
6. therapy system according to claim 1, wherein, described neurotransmitter supplement have the form being suitable for transdermal administration.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US13/162,446 US9079030B2 (en) | 2004-12-22 | 2011-06-16 | Systems and methods for balancing and maintaining the health of the human autonomic nervous system |
| US13/162,446 | 2011-06-16 | ||
| PCT/US2011/042360 WO2012173634A1 (en) | 2011-06-16 | 2011-06-29 | Systems and methods for balancing and maintaining the health of the human autonomic nervous system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103547240A CN103547240A (en) | 2014-01-29 |
| CN103547240B true CN103547240B (en) | 2016-03-30 |
Family
ID=47357391
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201180070951.0A Active CN103547240B (en) | 2011-06-16 | 2011-06-29 | For the autonomic balance of the mankind and the system and method maintaining health |
Country Status (2)
| Country | Link |
|---|---|
| CN (1) | CN103547240B (en) |
| WO (1) | WO2012173634A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111818959B (en) * | 2018-03-08 | 2022-09-09 | 西铁城时计株式会社 | Heart rate adjusting device |
| CN114052736B (en) * | 2021-08-31 | 2024-04-05 | 北京未名脑脑科技有限公司 | System and method for evaluating cognitive function |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5084007A (en) * | 1989-08-11 | 1992-01-28 | Malin David H | Method for chemical promotion of the effects of low current transcranial electrostimulation |
| CN1592616A (en) * | 2000-11-20 | 2005-03-09 | H·隆德贝克有限公司 | GABA enhancers in the treatment of diseases relating to reduced neurosteroid activity |
| CN102083453A (en) * | 2008-06-06 | 2011-06-01 | 洛林国立高等理工学院 | Anxiolytic composition containing [alpha]s1-casein-derived peptides |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2432810A1 (en) * | 2003-06-19 | 2004-12-19 | Andres M. Lozano | Method of treating depression, mood disorders and anxiety disorders by brian infusion |
| US7141028B2 (en) * | 2003-12-17 | 2006-11-28 | Mcnew Barry | Apparatus, system, and method for creating an individually, balanceable environment of sound and light |
| US20060136009A1 (en) * | 2004-12-22 | 2006-06-22 | Staffel Edward R | Dental/medical anxiety/phobia remediation protocol |
-
2011
- 2011-06-29 CN CN201180070951.0A patent/CN103547240B/en active Active
- 2011-06-29 WO PCT/US2011/042360 patent/WO2012173634A1/en active Application Filing
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5084007A (en) * | 1989-08-11 | 1992-01-28 | Malin David H | Method for chemical promotion of the effects of low current transcranial electrostimulation |
| CN1592616A (en) * | 2000-11-20 | 2005-03-09 | H·隆德贝克有限公司 | GABA enhancers in the treatment of diseases relating to reduced neurosteroid activity |
| CN102083453A (en) * | 2008-06-06 | 2011-06-01 | 洛林国立高等理工学院 | Anxiolytic composition containing [alpha]s1-casein-derived peptides |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2012173634A1 (en) | 2012-12-20 |
| CN103547240A (en) | 2014-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9079030B2 (en) | Systems and methods for balancing and maintaining the health of the human autonomic nervous system | |
| Teale et al. | Cortical source estimates of gamma band amplitude and phase are different in schizophrenia | |
| Grimaldi et al. | Neurostimulation techniques to enhance sleep and improve cognition in aging | |
| Petrocchi et al. | Transcranial direct current stimulation enhances soothing positive affect and vagal tone | |
| Urakami et al. | Sleep spindles—as a biomarker of brain function and plasticity | |
| WO2006071268A1 (en) | Dental/medical anxiety/phobia remediation protocol | |
| US20190321585A1 (en) | Non-pharmaceutical methods of mitigating addiction withdrawal symptoms | |
| Paleczny et al. | Inspiratory-and expiratory-gated transcutaneous vagus nerve stimulation have different effects on heart rate in healthy subjects: preliminary results | |
| Chen et al. | Autonomic/central coupling benefits working memory in healthy young adults | |
| Laufer et al. | Psychophysiological effects of coloured lighting on older adults | |
| CN103547240B (en) | For the autonomic balance of the mankind and the system and method maintaining health | |
| WO2021236421A1 (en) | Methods and systems for treating anxiety and depression | |
| Clauss | Disorders of consciousness and pharmaceuticals that act on oxygen based amino acid and monoamine neurotransmitter pathways of the brain | |
| do Amaral MSc et al. | The effects of musical auditory stimulation of different intensities on geometric indices of heart rate variability | |
| US11536965B2 (en) | Technologies for multi-randomized audio-visual entrainment | |
| US11813476B1 (en) | Methods of treating the brain and nervous system using light therapy | |
| RU2501584C1 (en) | Method of treating encephalopathy in children | |
| WO2020172448A1 (en) | Non-pharmaceutical methods of mitigating addiction withdrawal symptoms | |
| Divya et al. | Music Therapy for Stress Control and Autism | |
| Ruiz-Tristan et al. | Estradiol and Progesterone as key modulators of central systems implicated in schizophrenia | |
| Tukaiev et al. | Non-invasive vagus nerve stimulation attenuates the burnout | |
| Sculthorpe et al. | Does phase-modulation of applied 40-Hz transcerebral magnetic fields affect subjective experiences and hypnotic induction? | |
| Levkov | The Effects of Dance on Motor and Non-Motor Functions, and Resting State Electroencephalography in Individuals With Parkinson's Disease and Age-Matched Controls | |
| Yuminaga et al. | Changes in Electroencephalography Signals During Massage | |
| Aftanas et al. | Linkage of brain oscillatory systems with the cognitive (experience and valence) and physiological (cardiovascular reactivity) components of the emotions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant |